Effects of serotoninergic drugs on tremor induced by physostigmine in rats

S. Sarkar, Bobby Thomas, D. Muralikrishnan, K. P. Mohanakumar

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

We investigated the effects of various serotoninergic drugs and serotonin (5-HT) depletion on physostigmine-induced visible tremor in rats. Physostigmine (0.25-1.5 mg/kg) caused dose-dependent tremor, initiated at 3-5 min (latency decreases as dose increases) and lasted for 30-35 min. Serotonin agonists, 8-hydroxy-2-(di-n-propylamino) tetralin (2.5 mg/kg) and buspirone (5 mg/kg) augmented the tremor response caused by physostigmine. The 5-HT1/5-HT2 receptor antagonist, metergoline (1 mg/kg), and 5-HT2 blocker, cyproheptadine (10 mg/kg) significantly decreased the duration (40%) as well as intensity (45-50%) of physostigmine-tremor. The 5-HT(2a)/5-HT(2c) antagonist ritanserin (5 mg/kg) significantly reduced the duration (60%) without affecting the intensity of the tremor. In 5-HT depleted rats (p-chlorophenylalanine; 300 mg/kg, for 3 days), physostigmine failed to produce tremor. Interestingly, in these animals, administration of a non-specific 5-HT agonist, 5-methoxy-N,N-dimethyl tryptamine, caused high intensity tremor. These results suggest that presence of 5-HT at the pre-synaptic terminals is needed for the tremor response by physostigmine and the response is greatly mediated via post-synaptic 5-HT receptors. The overall data indicated a direct involvement of central 5-HT system in the cholinergic tremor induced by physostigmine. Copyright (C) 2000 Elsevier Science B.V.

Original languageEnglish (US)
Pages (from-to)187-193
Number of pages7
JournalBehavioural Brain Research
Volume109
Issue number2
DOIs
StatePublished - May 1 2000

Fingerprint

Physostigmine
Tremor
Pharmaceutical Preparations
Serotonin
Serotonin Receptor Agonists
Metergoline
Ritanserin
Fenclonine
Serotonin Agents
Cyproheptadine
Serotonin 5-HT2 Receptor Antagonists
Buspirone
8-Hydroxy-2-(di-n-propylamino)tetralin
Serotonin Antagonists
Serotonin Receptors
Presynaptic Terminals
Cholinergic Agents

Keywords

  • 5-HT involvement
  • Cholinergic tremor
  • Physostigmine
  • Serotonin depletion
  • Serotonin receptors
  • Tremor

ASJC Scopus subject areas

  • Behavioral Neuroscience

Cite this

Effects of serotoninergic drugs on tremor induced by physostigmine in rats. / Sarkar, S.; Thomas, Bobby; Muralikrishnan, D.; Mohanakumar, K. P.

In: Behavioural Brain Research, Vol. 109, No. 2, 01.05.2000, p. 187-193.

Research output: Contribution to journalArticle

Sarkar, S, Thomas, B, Muralikrishnan, D & Mohanakumar, KP 2000, 'Effects of serotoninergic drugs on tremor induced by physostigmine in rats', Behavioural Brain Research, vol. 109, no. 2, pp. 187-193. https://doi.org/10.1016/S0166-4328(99)00171-0
Sarkar, S. ; Thomas, Bobby ; Muralikrishnan, D. ; Mohanakumar, K. P. / Effects of serotoninergic drugs on tremor induced by physostigmine in rats. In: Behavioural Brain Research. 2000 ; Vol. 109, No. 2. pp. 187-193.
@article{0fbaf3c43d874efdba1f795a909be437,
title = "Effects of serotoninergic drugs on tremor induced by physostigmine in rats",
abstract = "We investigated the effects of various serotoninergic drugs and serotonin (5-HT) depletion on physostigmine-induced visible tremor in rats. Physostigmine (0.25-1.5 mg/kg) caused dose-dependent tremor, initiated at 3-5 min (latency decreases as dose increases) and lasted for 30-35 min. Serotonin agonists, 8-hydroxy-2-(di-n-propylamino) tetralin (2.5 mg/kg) and buspirone (5 mg/kg) augmented the tremor response caused by physostigmine. The 5-HT1/5-HT2 receptor antagonist, metergoline (1 mg/kg), and 5-HT2 blocker, cyproheptadine (10 mg/kg) significantly decreased the duration (40{\%}) as well as intensity (45-50{\%}) of physostigmine-tremor. The 5-HT(2a)/5-HT(2c) antagonist ritanserin (5 mg/kg) significantly reduced the duration (60{\%}) without affecting the intensity of the tremor. In 5-HT depleted rats (p-chlorophenylalanine; 300 mg/kg, for 3 days), physostigmine failed to produce tremor. Interestingly, in these animals, administration of a non-specific 5-HT agonist, 5-methoxy-N,N-dimethyl tryptamine, caused high intensity tremor. These results suggest that presence of 5-HT at the pre-synaptic terminals is needed for the tremor response by physostigmine and the response is greatly mediated via post-synaptic 5-HT receptors. The overall data indicated a direct involvement of central 5-HT system in the cholinergic tremor induced by physostigmine. Copyright (C) 2000 Elsevier Science B.V.",
keywords = "5-HT involvement, Cholinergic tremor, Physostigmine, Serotonin depletion, Serotonin receptors, Tremor",
author = "S. Sarkar and Bobby Thomas and D. Muralikrishnan and Mohanakumar, {K. P.}",
year = "2000",
month = "5",
day = "1",
doi = "10.1016/S0166-4328(99)00171-0",
language = "English (US)",
volume = "109",
pages = "187--193",
journal = "Behavioural Brain Research",
issn = "0166-4328",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Effects of serotoninergic drugs on tremor induced by physostigmine in rats

AU - Sarkar, S.

AU - Thomas, Bobby

AU - Muralikrishnan, D.

AU - Mohanakumar, K. P.

PY - 2000/5/1

Y1 - 2000/5/1

N2 - We investigated the effects of various serotoninergic drugs and serotonin (5-HT) depletion on physostigmine-induced visible tremor in rats. Physostigmine (0.25-1.5 mg/kg) caused dose-dependent tremor, initiated at 3-5 min (latency decreases as dose increases) and lasted for 30-35 min. Serotonin agonists, 8-hydroxy-2-(di-n-propylamino) tetralin (2.5 mg/kg) and buspirone (5 mg/kg) augmented the tremor response caused by physostigmine. The 5-HT1/5-HT2 receptor antagonist, metergoline (1 mg/kg), and 5-HT2 blocker, cyproheptadine (10 mg/kg) significantly decreased the duration (40%) as well as intensity (45-50%) of physostigmine-tremor. The 5-HT(2a)/5-HT(2c) antagonist ritanserin (5 mg/kg) significantly reduced the duration (60%) without affecting the intensity of the tremor. In 5-HT depleted rats (p-chlorophenylalanine; 300 mg/kg, for 3 days), physostigmine failed to produce tremor. Interestingly, in these animals, administration of a non-specific 5-HT agonist, 5-methoxy-N,N-dimethyl tryptamine, caused high intensity tremor. These results suggest that presence of 5-HT at the pre-synaptic terminals is needed for the tremor response by physostigmine and the response is greatly mediated via post-synaptic 5-HT receptors. The overall data indicated a direct involvement of central 5-HT system in the cholinergic tremor induced by physostigmine. Copyright (C) 2000 Elsevier Science B.V.

AB - We investigated the effects of various serotoninergic drugs and serotonin (5-HT) depletion on physostigmine-induced visible tremor in rats. Physostigmine (0.25-1.5 mg/kg) caused dose-dependent tremor, initiated at 3-5 min (latency decreases as dose increases) and lasted for 30-35 min. Serotonin agonists, 8-hydroxy-2-(di-n-propylamino) tetralin (2.5 mg/kg) and buspirone (5 mg/kg) augmented the tremor response caused by physostigmine. The 5-HT1/5-HT2 receptor antagonist, metergoline (1 mg/kg), and 5-HT2 blocker, cyproheptadine (10 mg/kg) significantly decreased the duration (40%) as well as intensity (45-50%) of physostigmine-tremor. The 5-HT(2a)/5-HT(2c) antagonist ritanserin (5 mg/kg) significantly reduced the duration (60%) without affecting the intensity of the tremor. In 5-HT depleted rats (p-chlorophenylalanine; 300 mg/kg, for 3 days), physostigmine failed to produce tremor. Interestingly, in these animals, administration of a non-specific 5-HT agonist, 5-methoxy-N,N-dimethyl tryptamine, caused high intensity tremor. These results suggest that presence of 5-HT at the pre-synaptic terminals is needed for the tremor response by physostigmine and the response is greatly mediated via post-synaptic 5-HT receptors. The overall data indicated a direct involvement of central 5-HT system in the cholinergic tremor induced by physostigmine. Copyright (C) 2000 Elsevier Science B.V.

KW - 5-HT involvement

KW - Cholinergic tremor

KW - Physostigmine

KW - Serotonin depletion

KW - Serotonin receptors

KW - Tremor

UR - http://www.scopus.com/inward/record.url?scp=0034070574&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034070574&partnerID=8YFLogxK

U2 - 10.1016/S0166-4328(99)00171-0

DO - 10.1016/S0166-4328(99)00171-0

M3 - Article

VL - 109

SP - 187

EP - 193

JO - Behavioural Brain Research

JF - Behavioural Brain Research

SN - 0166-4328

IS - 2

ER -